NOKOMIS, Fla.–(BUSINESS WIRE)–

The market for effective new treatments for Parkinsons disease and other degenerative neurological disorders is strong and projected to grow sharply in coming years. Thats good news for Rainbow Coral Corp.s (RBCC) biotech subsidiary, Rainbow Biosciences, as it closes in on a deal with Amarantus Biosciences, Inc. (AMBS)

The increasing market potential for Parkinsons therapies is what initially attracted RBCCs attention to Amarantus work. The Parkinson’s Disease Foundation estimates that as many as one million Americans suffer from Parkinson’s disease, and 60,000 new patients are diagnosed each year. Medication costs per person are believed to be around $2,500 each year and the total economic impact is estimated to be around $25 billion in the U.S. alone.

Most encouraging of all, the market for Parkinsons drugs could grow to a value of $3.75 billion by 2015, according to a report last year by Visiongain.

Growth in the Parkinson’s treatment market is being driven by new breakthroughs, and RBCC is working to help advance the timeline for a cure for the debilitating disease. RBCC is currently negotiating a potential definitive agreement with Amarantus, a company that could be on the verge of promising new diagnostic and therapeutic tools for Parkinsons patients and their doctors.

Amarantus owns the rights to a promising therapeutic protein known as MANF that prevents a type of cell death called apoptosis that could be the beginning of a cure for the disease. The company also owns the license to a groundbreaking diagnostic platform called NuroPro for Parkinsons that allows neurologists to accurately diagnose and track the progression of Parkinsons disease in patients. This groundbreaking test could potentially be on market in certain regions as early as 2013.

For more information on RBCCs biotechnology initiatives, please visit http://www.rainbowbiosciences.com/investors.html.

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit http://www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

View original post here:
Projected Growth in $3 Billion Parkinson’s Treatment Market Gives RBCC a Bright Outlook

Source:
http://www.longevitymedicine.tv/feed/

University of Rochester neurologists as well as families touched by Parkinsons disease will be hitting the pavement this weekend to raise awareness and funds to help fight the disease.

The local Moving Day celebration, which includes a walk and other activities aimed at Parkinsons disease, is this Sunday, Sept. 16, on the grounds of Monroe Community College. While the actual walk begins at 10:30 a.m. and ends at noon, registration opens at 8:30 a.m. In addition to the walk, several events revolving around movement a key difficulty for patients with the disease will be held throughout the morning, including dance, yoga, Tai Chi, vocal and other physical exercises.

Moving Day is sponsored by the National Parkinson Foundation, which works to improve the quality of life for people with the disease through research, education and outreach. The goal of the Rochester Chapter of NPF this year is $65,000; so far the group has raised $26,000, already more than the total achieved last year. Funds will go to support the National Parkinson Foundation and its Rochester chapter, as well as Parkinsons research at the Medical Center.

Vicki Aspridy, registrar at the Simon School, is a member of the local chapter and part of the planning committee for the event. She is helping to organize Moving Day in honor of her mother, who had the disease late in life and passed away four years ago. A University team is being organized by neurologist Michelle Burack, M.D., Ph.D., who treats patients with the disease and also does research aimed at understanding and reducing the symptoms that patients experience.

For more information, visit http://MovingDayRochester.org.

Link:
Moving Day to benefit National Parkinson Foundation held Sunday at MCC

Source:
http://www.longevitymedicine.tv/feed/

Parkinsons disease may prove to be no match for a team of UH researchers at the Center of Nuclear Receptors and Cell Signaling.

CNRCS Director Jan-ke Gustafsson and professor Margaret Warner, along with their team of researchers, have found a link between beta-sitosterol present in many plants and good for preventing cholesterol absorption from ones diet and ALS-Parkinsons disease. This discovery may aid in the fight against Parkinsons and was recently published in Proceedings of the National Academy of Sciences.

Parkinsons disease is a chronic progressive neurological disease linked to a decrease in dopamine, production in the substantia nigra and marked by tremors in resting muscles, rigidity, slowness of movement, impaired balance and a shuffling gait.

If ALS-Parkinsons patients do have a defect in LXRbeta signaling, they will benefit from pharmaceuticals which target signaling of this receptor. Many such drugs are being developed at present, Warner said.

Authors Yubing Dai and Wanfu Wu researching in the CNRCS lab. | Amanda Hilow/The Daily Cougar

Gustafsson has had a long-standing interest in nuclear receptors because they are activated by the small molecules like hormones, and medication can be developed to increase or decrease their activity. In 1995, Gustafssons lab discovered two novel nuclear receptors one was LXRbeta. An efficient way to unmask the function of the newly discovered genes is to use gene technology to eliminate the hormone in mice and see what happens.

The receptor continues to show promise as a potential therapeutic target for this disease, as well as other neurological disorders, Gustafsson said in a press release for HealthNewsDigest.com. LXRbeta performs an important function in the development of the central nervous system, and our work indicates that the presence of LXRbeta promotes the survival of dopaminergic neurons, which are the main source of dopamine in the central nervous system.

During World War II, ALS-Parkinsons disease was prevalent in the Pacific Islands and Guam where there was a shortage of wheat. During that time, people had to make bread from cycad seeds, which contain a high level of beta-sitosterol.

The reason for the susceptibility of certain people in Guam to toxicity from beta-sitosterol remained a mystery until we developed the LXRbeta knockout mice, Warner said. These mice develop ALS-Parkinsons disease spontaneously as they age, and the disease is made worse if beta-sitosterol is added to their diet.

However, it was discovered that LXRbeta knockout mice did not need to be fed beta-sitosterol to develop Parkinsons disease. Meaning UH researchers have to look for the possibility that people develop ALS- Parkinsons disease because of defective LXRbeta signaling.

The rest is here:
Researchers battle Parkinson’s disease using mouse model

Source:
http://www.longevitymedicine.tv/feed/

Tom and Carol Reid, of Plum, have been living with Parkinsons disease for 17 years, but its how they are helping others with the disorder that has earned them a big honor.

They will be awarded with the Local Hero award Saturday from the Davis Phinney Foundation.

Carol Reid remembers when she started noticing a change in her husband.

He was losing facial expression. I didn’t know what that meant. I just felt like you know, you’re not responding to me, she said. He was drooling. His eyes were watering. He was falling often.

Tom Reid went to the family doctor and was given Claritin for his watery eyes.

It took two years to get a second opinion and a diagnosis of Parkinsons, a neurodegenerative disease.

I was in a classical case of denial, said Tom.

Symptoms involve loss of motor control, affecting speech and movement.

Tom was a captain in the Army before becoming a corporate attorney. He enjoyed public speaking and using what he and his wife called his command voice.

Parkinsons has changed that.

Original post:
Pittsburgh-area couple awarded for work with Parkinson's disease patients

Source:
http://www.longevitymedicine.tv/feed/

PARKINSONS & MEMORY: In addition to the motor symptoms in Parkinson’s disease, there are also cognitive symptoms which may be evident even in the early stages of the disease. These may include deficits in executive function (especially planning and attention), set-shifting (ability to alternate between two or more tasks), and memory. Approximately 25%-30% of Parkinson’s patients develop dementia. It is not yet known whether dementia is actually a symptom of Parkinson’s disease or whether patients with Parkinson’s disease are for some reason also at higher risk for dementia. A large number of Parkinson’s patients also experience psychiatric disorders such as depression, anxiety, or sleep disorders.

Because Parkinson’s disease damages neurons in the substantia nigra which produce dopamine, treatment usually involves drugs which work to counteract this shortage of dopamine. Parkinson’s patients may benefit from treatment with several kinds of drugs simultaneously. These drugs can often combat the motor symptoms for a long time, but as the disease progresses and the substantia nigra continues to degrade, the drugs eventually become less effective.

Some patients whose motor symptoms cannot be controlled by medication undergo brain surgery to destroy portions of the brain regions responsible for some of the motor symptoms in Parkinson’s disease, or benefit from deep brain stimulation (DBS) — using thin wires to stimulate electrical activity in the brain. There has also been controversial research involving implantation of cells from aborted fetuses into the brains of Parkinson’s patients in an attempt to regrow neurons in the substantia nigra; more recently, scientists are exploring the possibility of using stem cells isolated from healthy adults or grown in the laboratory. As yet, this work is still highly experimental. (Source: Memorylossonline.com)

UNIVERSITY OF MARLYAND STUDY: Researchers are looking to study the benefits of exercise for fitness, walking, balance, and memory. They are still enrolling participants, and those eligible for the study are people who have been diagnosed with Parkinsons disease and have mild to moderate gait or balance difficulty. The study is being conducted at the Veterans Affairs Medical Center at the University of Maryland School of Medicine in Baltimore, Maryland.

Link:
Brain Games Help Parkinson’s Patients

Source:
http://www.longevitymedicine.tv/feed/

The U.S. FDA this week approved a once-a-day pill for the treatment of multiple sclerosis (MS). The pill, being branded as Aubagio by Sanofi S.A., is specifically for the treatment of adults with relapsing forms of MS.

In a clinical trial, the relapse rate for patients using Aubagio was about 30 percent lower than the rate for those taking a placebo, said Dr. Russell Katz, director of the division of neurology products in the FDAs Center for Drug Evaluation and Research. Multiple sclerosis can impair movement, sensation, and thinking, so it is important to have a variety of treatment options available to patients.

According to the National Institutes of Health, MS is a chronic autoimmune disease that affects the central nervous system. It disrupts the communication between the brain and the body, causing motor skill disruption for nearly every part of the body, depending on which nerves in the brain are damaged.

As for the drug itself, side effects seen during drug trials included diarrhea, abnormal liver tests, nausea, and hair loss. Also, the box warnings for the drug warn of possible liver problems and fetal harm, including the risk of birth defects. Doctors will have to check patients liver function and give a pregnancy test before starting treatment with Aubagio.

Many people living with MS struggle with the additional burden of injectable therapies administered daily to weekly, said Dr. Aaron Miller, medical director at the center for multiple sclerosis at Mount Sinai Medical Center. The FDAs approval of Aubagio, a new oral treatment option, is an encouraging advancement for the MS community and may be a valuable treatment for people living with this often debilitating disease.

Go here to read the rest:
Multiple Sclerosis Pill Approved by U.S. FDA

Source:
http://www.longevitymedicine.tv/feed/

Sanofi SA has won U.S. approval for its multiple sclerosis pill Aubagio – one of the two treatments for the chronic disease that could return the French drugmaker to growth after several blockbuster drugs lost patent protection.

The drug has been shown to be less effective than some rivals but has milder side effects and analysts say it could find favor among newly diagnosed patients. Around 35 percent to 40 percent of multiple sclerosis (MS) sufferers prefer to take no medication rather than face unwanted side effects.

“In a clinical trial, the relapse rate for patients using Aubagio was about 30 percent lower than the rate for those taking a placebo,” Russell Katz, director of the Division of Neurology Products at the Food and Drug Administration, said in a statement on Wednesday.

Aubagio is expected to launch on the U.S. market in a few weeks, a spokeswoman for Sanofi unit Genzyme said.

Multiple sclerosis, which has no cure, affects 2.5 million people worldwide. It is a chronic, often disabling disease that attacks the central nervous system and can lead to numbness, paralysis and loss of vision.

MS drugs Gilenya by Novartis and Biogen Idec Inc’s BG-12 are expected to dominate a market that JPMorgan analysts predict growing to $14 billion in 2015 from $9.6 billion last year.

Aubagio is seen grabbing a much smaller chunk of this market, reaching modest sales of $353 million in the United States and five major European countries by 2020, according to business intelligence firm Datamonitor.

Cheuvreux analyst Marcel Brand, who has a more optimistic forecast, predicts peak sales of Aubagio of 1.48 billion euros by 2018. “Although Aubagio is not as effective on relapse rates as Gilenya, it’s free of its longer-term side effects,” he said.

Patients taking Gilenya have to be monitored because the drug causes the heart rate to slow down in the first hours after ingestion.

European regulators are expected to give their response to Aubagio in the first quarter of 2013.

Here is the original post:
Sanofi multiple sclerosis pill gets US approval

Source:
http://www.longevitymedicine.tv/feed/

DUBLIN–(BUSINESS WIRE)–

Research and Markets (http://www.researchandmarkets.com/research/k4b4f3/global_multiple_sc) has announced the addition of the “Global Multiple Sclerosis Drug Pipeline Capsule – 2012″ report to their offering.

This report is an outline of all the key research and development (R&D) activities of the global Multiple Sclerosis drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the Multiple Sclerosis drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:

– Multiple Sclerosis: Overview

– Multiple Sclerosis Drug Pipeline Overview

– Multiple Sclerosis Phase 3 Clinical Trial Drug Pipeline Insights

– Multiple Sclerosis Phase 2 Clinical Trial Drug Pipeline Insights

See the original post here:
Research and Markets: Global Multiple Sclerosis Drug Pipeline Capsule – 2012

Source:
http://www.longevitymedicine.tv/feed/

By Matt McMillen WebMD Health News

Reviewed by Laura J. Martin, MD

Sept. 13, 2012 — The FDA has approved Aubagio (teriflunomide), a new drug for the treatment of multiple sclerosis (MS). The once-a-day tablet will be prescribed to adults with relapsing forms of the chronic, incurable disease.

In a two-year study, the Aubagio reduced yearly relapses by nearly a third compared to placebo. It also slowed the progression of the disease.

“We are greatly encouraged to see a new oral therapeutic option become available to people living with MS,” said Timothy Coetzee, PhD, chief research officer at the National MS Society, in a news release issued by the drug’s developer, Genzyme.

MS is the most common disabling neurological disease among young adults, according to the National Institute of Neurological Disorders and Stroke. About 400,000 people in the U.S. have MS. As many as two-thirds of them are women. The disease is usually diagnosed between the ages of 20 and 50.

MS often gradually worsens over time. It causes fatigue, pain, vision and muscle problems, and other difficulties.

Aubagio does not come without risks. The drug’s label will include a boxed warning that alerts to the risk of potentially fatal liver problems. The label advises that patients’ liver function should be tested before starting Aubagio and while on the drug.

The box warning also mentions the risk of birth defects. Women should not be pregnant when they start the drug and must use birth control while taking it.

Other possible side effects include diarrhea, abnormal liver tests, nausea, and hair loss.

Visit link:
FDA Approves New Multiple Sclerosis Drug Aubagio

Source:
http://www.longevitymedicine.tv/feed/

Editor’s Choice Main Category: Multiple Sclerosis Also Included In: Regulatory Affairs / Drug Approvals Article Date: 15 Sep 2012 – 0:00 PDT

Current ratings for: Aubagio (teriflunomide) Approved For Multiple Sclerosis Treatment, FDA

1.5 (2 votes)

According to experts, the Multiple Sclerosis prescribing market is worth $12 billion annually. If Aubagio becomes popular, it has the potential to become a major earner for its makers, Sanofi-Aventis. However, it is entering a highly-competitive market with very effective existing medications. Novartis’ Gilenya and Tysabri from Elan Corp are said to be more effective than teriflunomide.

Director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research, Russell Katz, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research, said:

Multiple sclerosis is a long-term autoimmune, inflammatory disease of the central nervous system. Communication between the brain and other parts of the body are disrupted. Multiple Sclerosis is one of the most common causes of neurological disability in young adults. Twice as many females live with MS than males.

People with MS have episodes of relapses (worsening function), followed by remissions (recovery). Eventually, remission periods may be incomplete as the disease progresses. Aubagio has been approved for the initial phases of the disease.

According to clinical trial results, the following side effects among people taking Aubagio were reported: hair loss, nausea, abnormal liver test results, and diarrhea.

Aubagio contains a Boxed Warning explaining to doctors and their patients that there is a risk of liver problems, which may sometimes be fatal, as well as birth defects. Doctors should carry out blood tests beforehand to make sure liver function is normal. During treatment with Aubagio, liver functions tests should be performed periodically.

The Boxed Warning also alerts prescribers and their patients about some animal studies which linked the drug with a higher risk of fetal harm. That is why Aubagio is labeled as a Pregnancy Category X drug, meaning that female patients of childbearing age should have negative pregnancy test results (and use effective birth control therapy) before being considered for Aubagio treatment.

Read the original:
Aubagio (teriflunomide) Approved For Multiple Sclerosis Treatment, FDA

Source:
http://www.longevitymedicine.tv/feed/

ScienceDaily (Sep. 13, 2012) Many people with multiple sclerosis for years have taken the natural supplement Gingko biloba, believing it helps them with cognitive problems associated with the disease.

But the science now says otherwise. A new study published in the journal Neurology says Gingko biloba does not improve cognitive performance in people with multiple sclerosis. The research was published in the Sept. 5, 2012, issue of Neurology, the medical journal of the American Academy of Neurology. The current study was a more extensive look at the question after a smaller 2005 pilot study suggested there might have been some cognitive benefits in MS patients using the supplement. That study found that Gingko seemed to improve attention in MS patients with cognitive impairment.

But the larger follow-up study, conducted with patients at the Portland and Seattle Veterans Affairs medical centers, found no cognitive benefits to using Gingko.

“It’s important for scientists to continue to analyze what might help people with cognitive issues relating to their MS,” said Jesus Lovera, M.D., the study’s lead author, a former fellow at the Portland VA Medical Center and former instructor in Oregon Health & Science University’s Department of Neurology, where he did much of the work on the study. Lovera is now with the Department of Neurology at the Louisiana State University Health Sciences Center.

“We wanted to follow up on the earlier findings that suggested there may be some benefit. But we believe this larger study settles the question: Gingko simply doesn’t improve cognitive performance with MS patients,” said Lovera.

About one-half of people with MS will develop cognitive problems, and those cognitive problems can be debilitating in some people, said Dennis Bourdette, M.D., a co-author of the study, co-director of the VA MS Center of Excellence-West at the Portland VA Medical Center and chairman of the OHSU Department of Neurology. The most common problems relate to memory, attention and concentration, and information processing.

There is no known treatment that can improve cognition with MS patients — which is partly why MS patients and researchers had hoped that Gingko biloba could help.

Lovera was also the lead author in the 2005 study, conducted at OHSU. That study included 39 participants who were given Gingko biloba or a placebo. The new study included 120 participants given Gingko or a placebo.

The study was supported by a grant from the U.S. Department of Veterans Affairs Rehabilitation Research and Development Service.

Share this story on Facebook, Twitter, and Google:

Here is the original post:
Gingko biloba does not improve cognition in multiple sclerosis patients, study finds

Source:
http://www.longevitymedicine.tv/feed/

WASHINGTON, Sept. 11, 2012 /PRNewswire/ — As evidence increases showing that there may be a connection between hearing loss and dementia, the Better Hearing Institute (BHI) is urging hearing checks among Baby Boomers and Gen Xers. Because most hearing loss can be managed with hearing aids, BHI also is encouraging those with hearing loss to be fitted with hearing aids when appropriate. BHI’s outreach efforts come in recognition of World Alzheimer’s DaySeptember 21.

To make it easier for anyone to determine if they need a comprehensive hearing test by a hearing healthcare professional, BHI is offering a free, quick, and confidential online hearing check atwww.hearingcheck.org.

Several studies have looked at the relationship between hearing loss and cognitive function. One such study,conducted by researchers at Johns Hopkins and the National Institute on Aging, and published in theArchives of Neurology, found that seniors with hearing loss are significantly more likely to develop dementia over time than those who retain their hearing. The study also found that the more hearing loss they had, the higher their likelihood of developing dementia.

According to the Johns Hopkins press release on the study, the reason for the link between the two conditions is unknown, but the investigators suggest that a common pathology may underlie both or that the strain of decoding sounds over the years may overwhelm the brains of people with hearing loss, leaving them more vulnerable to dementia. They also speculate that hearing loss could lead to dementia by making individuals more socially isolated, a known risk factor for dementia and other cognitive disorders.

According to BHI, these research findings should prompt people to take hearing loss seriously. BHI encourages Boomers and Gen Xers especially to get their hearing tested by a hearing healthcare professional who can provide a thorough examination and, if needed, fit them for hearing aids.

In an effort to improve the quality of life for people with Alzheimer’s disease, BHI advocates that hearing checks, hearing healthcare, and hearing aids when appropriate, be included in their regimen of care. According to the Institute, unaddressed hearing loss can present an added, unnecessary strain on individuals with Alzheimer’s disease, and also on caregivers who suffer from hearing loss themselves. BHI also advocates that hearing checks and hearing healthcare be part of the diagnostic process.

Studies show that although a significantly higher percentage of people with Alzheimer’s disease may have hearing loss, they’re also much less likely to receive attention for their hearing needs than their normally aging peers.

Research also shows that the use of hearing aids among Alzheimer’s patients with hearing loss, in combination with appropriate aural rehabilitation in a multidisciplinary setting, can help alleviate the symptoms of depression, passivity, negativism, disorientation, anxiety, social isolation, feelings of helplessness, loss of independence and general cognitive decline.

Because healthy hearing helps people remain socially and cognitively engaged, BHI urges all Baby Boomers, Gen Xers, and others to make hearing checks a regular part of their preventive healthcare.

About Alzheimer’s Disease

Read more from the original source:
Dementia-Hearing Loss Link Prompts BHI to Urge Hearing Checks Among Baby Boomers, Gen Xers in Recognition of World …

Source:
http://www.longevitymedicine.tv/feed/

COLLIER COUNTY, FL –

A veteran dementia patient was found lying in the woods, nearly dead. Five years later, his family says they finally have justice.

“We needed justice for my grandfather and people needed to be held accountable for their actions,” said Dederick’s granddaughter Lauren Carey, who searched tirelessly for five days to find her missing grandfather.

Then 88-year-old Loren Dederick, who passed away last year, went missing in 2007 after a medical transport mix-up.

A jury found TLC Non-Emergency Medical Transport at fault ordered the company to pay Dederick’s family $700,000 for his injuries and mental anguish.

“He laid there for five days with no food or water and no way out,” said Dederick’s. “He was dirty, ant bites all over, dehydrated and just really scared.”

“He was getting close to the time where he probably couldn’t sustain himself any longer,” said Dederick’s daughter Donna Ward.

The World War II veteran was taken to NCH North Naples hospital for chest pain on September 21, 2007.

When he was released, NCH accidentally gave a TLC transport driver Dederick’s old address, the HarborChase assisted-living facility on Airport-Pulling Road in Naples.

The driver, 44-year-old Dimas Herrera, took Dederick to that wrong address. According to testimony, nurses at the assisted-living center told Herrera that Dederick didn’t live there.

See the original post here:
Dementia patient's family: "We needed justice"

Source:
http://www.longevitymedicine.tv/feed/

Australia is leading the world with the first publicly funded program aimed at reducing the risk of developing dementia.

A new brain health program, Your Brain Matters, will be launched by Alzheimer’s Australia this week.

It was funded by the federal government in the 2012 budget, the first prevention program for dementia in the world to receive public funding, said Alzheimer’s Australia chief executive Glenn Rees.

He said this showed the condition was being treated as a chronic disease, rather than a normal part of ageing.

Mr Rees said the program was a guide to keeping the brain healthy by exercising the mind and body and eating a nutritious diet.

“It’s important to understand that while there is, as yet, no cure for dementia there are things we can all do now – like keeping your brain active, being fit and healthy and looking after your heart – which may help to reduce our risk of developing dementia, or slow cognitive decline in those already diagnosed with dementia,” Mr Rees said in a statement.

He said there was evidence to suggest that if physical inactivity could be reduced in Australia by five per cent every five years, this could cut dementia prevalence by 11 per cent by 2051.

This would equate to about 100,000 fewer Australians living with dementia by addressing just one risk factor, he said.

International Alzheimer’s expert Dr Serge Gauthier, of McGill University in Canada, who is visiting Australia as part of Dementia Awareness Week, said prevention programs were vital to try to stem the incidence of dementia.

About 280,000 Australians have dementia, with this figure set to soar to almost one million by 2050.

View original post here:
National push to prevent dementia

Source:
http://www.longevitymedicine.tv/feed/